Fig. 1 · Structure

Documents & Downloads

Zofenopril calcium

Cat. No. A12769 CAS 81938-43-4

ACE inhibitor

Zofenopril calcium is an angiotensin-converting enzyme ACE inhibitor.

In Stock

Publications for Zofenopril calcium

3 publications citing this product

  1. E Saman, .et al. , Physiol Res, 2025, Dec 31;74(Suppl 2):S231-S244 PMID: 41532630
  2. Sona Cacanyiova, .et al. , Biol Res, 2023, Oct 25;56(1):55 PMID: 37875978
  3. Tomas Jasenovec, .et al. , Biomedicines, 2021, Dec 14;9(12):1902 PMID: 34944718

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In healthy mice, oral zofenopril calcium increased plasma and myocardial H₂S and nitrite at 8 h. H₂S changes were not significant at 1 or 24 h, and eNOS Ser1177 phosphorylation showed a nonsignificant trend (P=0.053). These findings support gasotransmitter modulation under the tested conditions; they do not provide a direct ACE-inhibition IC₅₀. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Zofenopril calcium Research Summary

This section summarizes 3 in vivo studies of Zofenopril calcium from 3 published references. In vivo models include male C57BL/6J mice, 10–14 weeks old.

Zofenopril calcium In Vivo Studies

In spontaneously hypertensive rats receiving MLN-4760, zofenopril calcium improved erythrocyte osmotic resistance. The deformability response was limited, and RBC DCF fluorescence did not significantly decrease. These are animal-treatment findings with subsequent blood assays. [2]

In obese Zucker diabetic fatty rats, four weeks of oral zofenopril calcium lowered systolic blood pressure and improved isolated-aorta relaxation and contraction relative to obese controls. The authors reported no significant improvement in glucose tolerance under their test conditions. [3]

Acute H2S and nitrite responses in healthy mice

Animal study · Male C57BL/6J mice, 10–14 weeks old [1]

A single oral dose increased H2S at 8 h, with no significant change at 1 or 24 h. Nitrite increased at 8 h. H2S-producing enzyme protein levels were unchanged; eNOS Ser1177 phosphorylation showed a nonsignificant trend. The ramipril comparator did not significantly alter these gasotransmitter endpoints. These measurements do not establish direct ACE potency or prove that the parent molecule directly releases H2S.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma and myocardial H2S at 8 h; time-course limitsmean ± SEM Plasma: 0.62±0.09 versus 0.36±0.04 μmol/L, P<0.05; myocardium: 0.87±0.12 versus 0.39±0.03 nmol/mg protein, P<0.01 (zofenopril versus vehicle). No significant difference at 1 or 24 h.[1]
Plasma and myocardial nitrite at 8 hmean ± SEM Plasma: 0.45±0.08 versus 0.25±0.04 μmol/L, P<0.05; myocardium: 9.67±0.73 versus 7.18±0.29 nmol/mg protein, P<0.01 (zofenopril versus vehicle).[1]
H2S enzyme proteins and eNOS phosphorylation/expression at 8 hsignificance CBS, CSE and 3-MST proteins: no significant change. eNOS Ser1177 phosphorylation: P=0.053; Thr495 phosphorylation and total eNOS: no significant change.[1]
H2S and nitrite after ramipril comparatorqualitative No significant changes in plasma or myocardial H2S or nitrite at 8 h versus vehicle.[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single dose
Treatment course
1, 8 or 24 h endpoints
Vehicle
Carboxymethylcellulose 0.2% m/v
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Zofenopril calcium
10 mg/kg
Vehicle; ramipril 3 mg/kg oral comparator in separate experimentsH2S and nitrite increased at 8 h; eNOS phosphorylation trend did not reach significance.[1]
Zofenopril calcium
Model: Healthy male C57BL/6J mice
Methods and source locations

Compound reported in the paper: Zofenopril calcium; Compound label in the paper: Calcium salt, Menarini Ricerche S.p.A.

Applies to the reported calcium-form material and animal conditions; no validation of this SKU or any Adooq lot.

Methods: Animals, Treatment, H2S and NO measurements, Western Blot, Statistical Analysis; Results associated with Figures 1–3

Plasma and myocardial H2S at 8 h; time-course limits: Gas chromatography/sulfur chemiluminescence; Figure 1: plasma n=8 zofenopril at 8 h, n=7 vehicle; myocardium n=13 per group. — Results: Zofenopril Increases H2S Bioavailability In Vivo; Figure 1A–B; H2S method

Plasma and myocardial nitrite at 8 h: HPLC; Figure 2: plasma n=12 zofenopril and n=13 vehicle; myocardium n=8 per group. — Results: Zofenopril Activates eNOS and Increases NO Bioavailability; Figure 2A–B; NO-metabolite method

H2S enzyme proteins and eNOS phosphorylation/expression at 8 h: Western blots normalized to GAPDH or total eNOS as labeled; n=8/group for H2S enzyme proteins, n=6/group for eNOS endpoints; mean±SEM. — Figures 1C–F and 2C–F; corresponding Results; Western Blot method

H2S and nitrite after ramipril comparator: Ramipril 3 mg/kg orally; Figures 3A–D; gas chromatography and HPLC. Separate vehicle groups; not a direct head-to-head superiority test. — Treatment: Murine study; Results: Ramipril, a Dicarboxylate ACEI, Does Not Affect H2S and NO Bioavailability; Figure 3A–D

Zofenopril calcium · Methods: Animals and Treatment; Figures 1–3

Erythrocyte responses after zofenopril with or without ACE2 inhibition

Animal study · Spontaneously hypertensive rats entering at 16 weeks; C n=12, CZ n=7, M n=12, MZ n=12 assigned [2]

Zofenopril improved osmotic resistance in MLN-4760-treated rats. Deformability showed an interaction but only a nonsignificant tendency to improve in untreated SHRs; no reduction in the RBC DCF fluorescence endpoint was detected. Ex vivo RBC readouts follow animal dosing and are represented as one animal study.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RBC osmotic resistanceNaCl concentration giving 50% hemolysis MZ versus M: improved osmotic resistance, p=0.037. Two-way ANOVA: zofenopril p=0.02; ACE2 inhibition p=0.016.[2]
RBC deformabilityinteraction and trend ACE2 inhibition × zofenopril interaction: p=0.013; CZ versus C tendency: p=0.074 (not significant).[2]
RBC DCF-related fluorescencequalitative Neither ACE2 inhibition nor zofenopril significantly affected DCF-related fluorescence.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CZ: zofenopril without MLN
10 mg/kg/day
C: no zofenopril; pump with 10% DMSO in isotonic salineDeformability tendency did not reach significance (p=0.074); no significant DCF fluorescence reduction.[2]
MZ: zofenopril plus MLN-4760
Zofenopril 10 mg/kg/day; MLN-4760 1 mg/kg/day
M: MLN-4760 without zofenoprilImproved osmotic resistance (p=0.037 versus M); no significant DCF fluorescence reduction.[2]
CZ: zofenopril without MLN
Model: Spontaneously hypertensive rats
Route: Oral, mixed with food
Frequency: Daily
Treatment course: Days 5–14
MZ: zofenopril plus MLN-4760
Model: Spontaneously hypertensive rats under pharmacological ACE2 inhibition
Route: Zofenopril oral in food; MLN subcutaneous pump
Frequency: Daily zofenopril; continuous MLN
Treatment course: Zofenopril days 5–14; MLN 14 days
Methods and source locations

Compound reported in the paper: Zofenopril calcium; Compound label in the paper: Zofenopril calcium, AdooQ Bioscience LLC

Applies to the reported calcium-form material and animal conditions; no validation of this SKU or any Adooq lot.

Methods 2.1, 2.7, 2.9, 2.11–2.12; Results 3.8, 3.10; Figures 4 and 6

RBC osmotic resistance: Whole-blood hypotonic NaCl hemolysis assay; IC50 here denotes the NaCl concentration producing 50% hemolysis, not drug potency. Results shown as mean±SD; no exact ordinate value inferred. — Methods 2.11–2.12; Results 3.8; Figure 4b and caption

RBC deformability: Filtration through 5 μm pores; fraction of cells passing filter. Figure displays mean±SD; endpoint sample sizes can differ after outlier removal. — Methods 2.7, 2.12; Results 3.8; Figure 4a

RBC DCF-related fluorescence: DCF fluorescence microscopy assay on isolated RBCs; mean±SD. This assay does not establish universal absence of oxidative stress. — Methods 2.9, 2.12; Results 3.10; Figure 6a

CZ: zofenopril without MLN · Methods 2.1; Results 3.8, 3.10; Figures 4a and 6a

MZ: zofenopril plus MLN-4760 · Methods 2.1; Results 3.8, 3.10; Figures 4b and 6a

Four-week vascular response in obese diabetic rats

Animal study · Male Zucker diabetic fatty rats: lean fa/+ (L), obese fa/fa (O), treated obese (OZ); n=8 per group [3]

Four weeks of zofenopril calcium reduced systolic blood pressure and improved aortic acetylcholine relaxation and noradrenaline contraction relative to obese controls. The reported glucose-tolerance test showed no significant treatment improvement; no general metabolic correction is inferred.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Terminal systolic blood pressurebetween-group significance OZ lower than O: p<0.01.[3]
Isolated thoracic-aorta relaxation and contraction after animal dosingbetween-group significance Acetylcholine relaxation improved in OZ versus O: p<0.001; noradrenaline contraction restored versus O: p<0.001.[3]
Post-treatment glucose tolerancequalitative No significant improvement after zofenopril treatment was reported.[3]

Conditions shared by the study groups

Route
Oral, mixed with food
Frequency
Daily
Treatment course
4 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
OZ: zofenopril-treated obese rats
15 mg/kg/day
Untreated obese fa/fa rats (O); lean fa/+ rats (L) as phenotype controlLower SBP and improved aortic reactivity; no significant improvement of glucose tolerance reported.[3]
OZ: zofenopril-treated obese rats
Model: Male obese fa/fa ZDF rats
Methods and source locations

Compound reported in the paper: Zofenopril calcium; Compound label in the paper: Zofenopril calcium, AdooQ Bioscience

Applies to the reported calcium-form material and animal conditions; no validation of this SKU or any Adooq lot.

Materials and Methods: Animals/design, Blood pressure measurements, Vascular reactivity studies, Statistical analysis, Drugs; Figure 1a–d and associated Results

Terminal systolic blood pressure: Tail-cuff plethysmography; mean of at least 5 stable readings per reported value; n=8/group, mean±SEM; one-way ANOVA with Bonferroni tests. No exact bar heights extracted. — Blood pressure measurements; Results associated with Figure 1a; Figure 1 caption

Isolated thoracic-aorta relaxation and contraction after animal dosing: Organ-bath tension recording; acetylcholine applied to noradrenaline-precontracted rings; relaxation expressed relative to precontraction. n=8/group, mean±SEM; two-way ANOVA/Bonferroni. No exact curve values inferred. — Vascular reactivity studies; Results associated with Figure 1c–d; Figure 1 caption

Post-treatment glucose tolerance: Intraperitoneal glucose-tolerance test; n=8/group, mean±SEM. The printed loading dose is unusual and is not adopted or corrected; interpretation is confined to the authors' reported comparison. — Intraperitoneal glucose tolerance test; Results associated with Figure 1b; Figure 1 caption

OZ: zofenopril-treated obese rats · Animals/design and Drugs methods; Figure 1a–d

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 81938-43-4
Applications ACE inhibitor
Formula 2(C22H22NO4S2).Ca
Molecular Weight 897.17
SMILES
C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3=CC=CC=C3.C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3=CC=CC=C3.[Ca+2]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 5 mg/mL (5.57 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Zofenopril calcium Research References

  1. [1] Erminia Donnarumma, Murtuza J. Ali, Amanda M. Rushing, et al. Zofenopril Protects Against Myocardial Ischemia–Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability Journal of the American Heart Association (2016). PMID: 27381758 DOI: 10.1161/jaha.116.003531 Source material
  2. [2] Tomas Jasenovec, Dominika Radosinska, Marta Kollarova, et al. Angiotensin System Modulations in Spontaneously Hypertensive Rats and Consequences on Erythrocyte Properties; Action of MLN-4760 and Zofenopril Biomedicines (2021). PMID: 34944718 DOI: 10.3390/biomedicines9121902 Source material
  3. [3] Ezgi SAMAN, Martina CEBOVA, Miroslava MAJZUNOVA, et al. Vasoactive Effects of Chronic Treatment with ACE Inhibitor Zofenopril in Zucker Obese Diabetic Rats: The Role of Nitroso and Sulfide Signalization Physiological Research (2025). PMID: 41532630 DOI: 10.33549/physiolres.935722 Source material

Publications

3 publications citing this product

  1. E Saman, .et al. , Physiol Res, 2025, Dec 31;74(Suppl 2):S231-S244 PMID: 41532630
  2. Sona Cacanyiova, .et al. , Biol Res, 2023, Oct 25;56(1):55 PMID: 37875978
  3. Tomas Jasenovec, .et al. , Biomedicines, 2021, Dec 14;9(12):1902 PMID: 34944718

Added to your cart

View Cart Checkout
Loading...